NASDAQ:ALDR - Alder Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alder Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.88 0.00 (0.00 %) (As of 10/22/2019) Add Compare Today's Range$18.88Now: $18.88▼$18.8850-Day Range$18.88MA: $18.88▼$18.8852-Week Range$8.39Now: $18.88▼$19.12VolumeN/AAverage Volume5.12 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/ABeta2.64 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALDR Previous Symbol CUSIPN/A CIK1423824 Webhttp://www.alderbio.com/ Phone425-205-2900Debt Debt-to-Equity Ratio1.74 Current Ratio8.94 Quick Ratio8.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.62 million Price / Sales977.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book11.73Profitability EPS (Most Recent Fiscal Year)($4.87) Net Income$-296,430,000.00 Net MarginsN/A Return on Equity-226.13% Return on Assets-66.86%Miscellaneous Employees202 Outstanding Shares83,840,000Market Cap$1.58 billion Next Earnings DateN/A OptionableOptionable Receive ALDR News and Ratings via Email Sign-up to receive the latest news and ratings for ALDR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALDR Rates by TradingView Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions What is Alder Biopharmaceuticals' stock symbol? Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR." How were Alder Biopharmaceuticals' earnings last quarter? Alder Biopharmaceuticals Inc (NASDAQ:ALDR) posted its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.01. View Alder Biopharmaceuticals' Earnings History. What price target have analysts set for ALDR? 11 brokerages have issued twelve-month price objectives for Alder Biopharmaceuticals' stock. Their forecasts range from $14.00 to $21.00. On average, they anticipate Alder Biopharmaceuticals' stock price to reach $18.44 in the next year. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Alder Biopharmaceuticals. What is the consensus analysts' recommendation for Alder Biopharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alder Biopharmaceuticals. What are Wall Street analysts saying about Alder Biopharmaceuticals stock? Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock: 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (10/15/2019) 2. Mizuho analysts commented, "We maintain our Neutral rating on the shares as we see limited catalysts for the shares prior to FDA approval; financing overhang as well as risks associated with commercial launch." (5/3/2019) 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and $14 PT on ALDR. Today (5/2), Alder reported 1Q19 earnings, including cash and STI, of $498.5M. With the BLA submission of eptinezumab (epti’) accepted by the FDA and with a PDUFA date set for February 2020, the company expects to launch the drug by early next year (1Q20), and we believe its cash on hand will enable it to fund building out a right-sized" neurology/headache-specialist focused sales force, as well as other launch prep this year; it started with the recent hiring of a chief commercial officer." (5/2/2019) Has Alder Biopharmaceuticals been receiving favorable news coverage? News articles about ALDR stock have trended extremely negative on Sunday, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alder Biopharmaceuticals earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Alder Biopharmaceuticals. Who are some of Alder Biopharmaceuticals' key competitors? Some companies that are related to Alder Biopharmaceuticals include ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), FibroGen (FGEN), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Allakos (ALLK) and Deciphera Pharmaceuticals (DCPH). What other stocks do shareholders of Alder Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Celgene (CELG), Celator Pharmaceuticals (CPXX), Micron Technology (MU), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX), Exelixis (EXEL) and Sarepta Therapeutics (SRPT). Who are Alder Biopharmaceuticals' key executives? Alder Biopharmaceuticals' management team includes the folowing people: Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)Mr. Carlos Campoy, Chief Financial Officer How do I buy shares of Alder Biopharmaceuticals? Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Alder Biopharmaceuticals' stock price today? One share of ALDR stock can currently be purchased for approximately $18.88. How big of a company is Alder Biopharmaceuticals? Alder Biopharmaceuticals has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Alder Biopharmaceuticals employs 202 workers across the globe.View Additional Information About Alder Biopharmaceuticals. What is Alder Biopharmaceuticals' official website? The official website for Alder Biopharmaceuticals is http://www.alderbio.com/. How can I contact Alder Biopharmaceuticals? Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected] MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 402 (Vote Outperform)Underperform Votes: 332 (Vote Underperform)Total Votes: 734MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: Asset Allocation, Balancing Your Investments
